Clinical trial registry record

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 16, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01577381
Last registry update
March 16, 2016
Status
Terminated
Phase
Phase 2
Sponsor
Pfizer
Enrollment
10
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
10
Population
ALL · 60 Years to 90 Years
Duration
2012-08-01 to 2013-10-01
Intervention
RN6G; Placebo
Comparator
Placebo
Outcomes measured
Mean Reduction (in Study Eye) in Rate of Growth of Geographic Atrophy (GA) at Day 309 — Baseline and Day 309; Mean Reduction (in Study Eye) in Rate of Growth of GA at Day 449 (End of Study) — Baseline and Day 449; Mean Best Corrected Visual Acuity (BCVA) at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month 15,…; Percentage Change From Baseline in BCVA Correct Number of Letters at 9, 12, 15 Months and End of Study — Baseline, Mont…; Percentage Change From Baseline in BCVA Correct Number of Lines at Months 9, 12, 15 Months and End of Study — Baseline,…; Mean Low Luminance Best Corrected Visual Acuity (LL-BCVA) at 9, 12, 15 Months and End of Study — Baseline, Month 9, Mon…; Percentage Change From Baseline in LL-BCVA Correct Number of Letters at 9, 12, 15 Months and End of Study — Baseline, M…; Percentage Change From Baseline in LL-BCVA Correct Number of Lines at 9, 12, 15 Months and End of Study — Baseline, Mon…; Change From Baseline in Contrast Sensitivity at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month…; Percentage Change From Baseline in Contrast Sensitivity at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month…; Change From Baseline in Reading Speed at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month 15, and…; Change From Placebo in Reading Speed at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month 15, and…; Percentage Change From Baseline in Reading Speed at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Mo…; Change From Baseline in Reading Acuity at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month 15, an…; Change From Placebo in Reading Acuity at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, Month 15, and…; Percentage Change From Baseline in Reading Acuity at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12, M…; Change From Baseline in Critical Print Size Reading at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12,…; Change From Placebo in Critical Print Size Reading at 9, 12, 15 Months and End of Study — Baseline, Month 9, Month 12,…; Number of Participants With Treatment-Emergent Laboratory Abnormalities — Day 85 and Day 169; Number of Participants With Abnormal Change From Baseline in Vital Signs — Screening, Days 28, 57, 85, 113, 141, and 169
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON